

public docket for the application at docket number MARAD–2022–0076.

The Act imposes a strict timeline for processing an application. When MARAD and USCG determine that an application is complete (*i.e.*, contains information sufficient to commence processing), the Act directs that all public hearings on the application be concluded within 240 days from the date the Notice of Application is published.

Within 45 days after the final hearing, the Governor of the ACS, in this case, the Governor of Louisiana, may notify MARAD of their approval, approval with conditions, or disapproval of the application. If such approval, approval with conditions, or disapproval is not provided to the Maritime Administrator by that time, approval shall be conclusively presumed. MARAD may not issue a license without the explicit or presumptive approval of the Governor of the ACS. During this 45-day period, the Governor may also notify MARAD of inconsistencies between the application and State programs relating to environmental protection, land and water use, and coastal zone management. In this case, MARAD may condition the license to make it consistent with such state programs (33 U.S.C. 1508(b)(1)). MARAD will not consider written approvals or disapprovals of the application from the Governor of the ACS until commencement of the 45-day period after the final public hearing for the Final Environmental Impact Statement is completed. The Maritime Administrator must render a decision on the application within 90 days after the final hearing.

Should a favorable record of decision be rendered and a license be issued, MARAD may include specific conditions related to design, construction, operations, environmental permitting, monitoring and mitigations, and financial responsibilities. If a license is issued, USCG, in coordination with other agencies as appropriate, would review and approve the deepwater port's engineering, design, and construction; operations/security procedures; waterways management and regulated navigation areas; maritime safety and security requirements; risk assessment; and compliance with domestic and international laws and regulations for vessels that may call on the port. The deepwater port would be designed, constructed, and operated in accordance with applicable codes and standards.

In addition, the installation of pipelines and other structures may require permits under Section 404 of the

Clean Water Act and Section 10 of the Rivers and Harbors Act, which are administered by the USACE.

Permits from the EPA may also be required pursuant to the provisions of the Clean Air Act, as amended, and the Clean Water Act, as amended.

Summary of the Application

The application proposes the ownership, construction, operation, and eventual decommissioning of the New Fortress Energy (“NFE”) Louisiana FLNG deepwater port (“DWP”) terminal approximately 16 nautical miles off the southeast coast of Grand Isle, Louisiana. The project is to source domestic natural gas from multiple supply hubs in the Southeast Louisiana local market, liquify, and export as liquefied natural gas (LNG) up to 2.8 million metric tonnes per annum (MTPA), from a deepwater port located in federal waters off Louisiana.

The project will involve the installation of two nominal 1.4 MTPA liquefaction systems (FLNG1 and FLNG2) installed in the West Delta Outer Continental Shelf Lease Block 38 (“WD–38”) in approximately 30 meters (98 feet) of water. Each system will contain three platforms consisting of natural gas processing, natural gas liquefaction, and utilities and accommodations. FLNG1 will incorporate self-elevating platforms (aka jack-up platforms or rigs), and FLNG2, which will be located adjacent to FLNG1, will utilize fixed platform structures. An additional self-elevating platform will house feed gas compressors. Other than temporary construction staging areas, there are no onshore facilities associated with the Project. Staging for construction, if needed, will utilize existing staging, laydown and warehouse space near Port Fourchon, Port Sulphur, or Venice.

The feed gas supply to the project will be transported to the WD–38 site via the existing Kinetica Energy Express, LLC (“Kinetica”) offshore natural gas pipeline system and two newly constructed, 24-inch pipeline laterals connecting the Kinetica pipeline system to the Project. The Kinetica pipeline has been in continuous natural gas service since it was placed in service. The pipeline pressure is currently operating at 750 pounds per square inch (“psi”) with an onshore Maximum Allowable Operating Pressure (“MAOP”) of 1,000 psi and an offshore MAOP of 1,250 psi.

Both FLNG1 and FLNG2 will be connected to a single Floating LNG Storage Unit (“FSU”) via a flexible, partially submerged, 220-meter cryogenic hose transfer system. The FSU will be positioned approximately 107

meters (350 feet) from the FLNGs. To export the LNG, the FSU will receive one (1) commercially traded LNG carrier (LNGC) at a time, which will have a nominal cargo capacity of approximately 125,000 m³ to 160,000 m³. The LNGCs will berth along the starboard side of the FSU and receive the LNG cargo through a ship-to-ship transfer cargo transfer system. The LNGC will approach the DWP and depart from the DWP using an extension to the established safety fairway, which serves maritime traffic calling at the Louisiana Offshore Oil Port. Approximately 40 LNGCs will call on the Project per year.

For more information please contact either Mr. Brian Barton, MARAD, or Ms. Galia Kaplan, as listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

Privacy Act

The electronic form of all comments received into the Federal Docket Management System can be searched by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). The DOT Privacy Act Statement can be viewed in the **Federal Register** published on April 11, 2000 (Volume 65, Number 70, pages 19477–78) or by visiting www.regulations.gov.

(Authority: 33 U.S.C. 1501, *et seq.*; 49 CFR 1.93(h))

By Order of the Acting Maritime Administrator.

T. Mitchell Hudson, Jr.,

Secretary, Maritime Administration.

[FR Doc. 2022–08757 Filed 4–22–22; 8:45 am]

BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

[Docket No. NHTSA–2022–0007]

Request for Comments on Barriers and Solutions for Submitting Toxicology Data to the Fatality Analysis Reporting System Pursuant to Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities

AGENCY: National Highway Traffic Safety Administration (NHTSA), Department of Transportation (DOT).

ACTION: Request for comments on barriers to and solutions for providing toxicological data on drug-impaired driving investigations of motor vehicle fatalities to the Fatality Analysis

Reporting System (FARS) that meet the recommendations described in *Recommendations for Toxicological Investigations of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update*.

SUMMARY: Section 25025 of the Infrastructure Investment and Jobs Act requires NHTSA to submit a report to Congress that, in accordance with recommendations made in *Recommendations for Toxicological Investigations of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update*, (1) “identifies any barriers the States encounter in submitting alcohol and drug toxicology results to the Fatality Analysis Reporting System;” and (2) “provides recommendations on how to address the barriers identified” pursuant to providing the data described in the above recommendations for toxicological investigations. This notice requests public comments on any barriers that States may encounter that would affect their ability to provide the toxicological data described in the 2021 Update of the *Recommendations* document to FARS, as well as recommendations to address those barriers identified.

DATES: The request for comments is effective on April 25, 2022.

ADDRESSES: You may submit comments identified by DOT Docket ID Number NHTSA–2022–0007 using any of the following methods:

Electronic submissions: Go to <https://www.regulations.gov>. Follow the on-line instructions for submitting comments.

Mail: Docket Management Facility, M–30, U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, Room W12–140, Washington, DC 20590.

Hand Delivery: West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

Fax: 1–202–493–2251.

Instructions: Each submission must include the Agency name and the Docket number for this Notice. Note that all comments received will be posted without change to <https://www.regulations.gov> including any personal information provided.

FOR FURTHER INFORMATION CONTACT: For more information, contact Dr. Randolph Atkins, Jr., Chief, Behavioral Research Division, NPD–310, National Highway Traffic Safety Administration, 1200 New Jersey Avenue SE, Washington, DC 20590; Telephone number: (202) 366–5597; Email: randolph.atkins@dot.gov.

SUPPLEMENTARY INFORMATION:

Background

There is a growing concern with drug impaired driving in the United States and around the globe. While alcohol is the drug most often linked to impaired driving and crashes, there are many other drugs that can impair driving ability and contribute to crashes.ⁱ Other potentially impairing drugs include some over-the-counter (OTC) drugs, some prescription drugs, and most illegal drugs. The use of drugs other than alcohol and in combination with alcohol is widespread. The National Survey on Drug Use and Health (NSDUH) estimated that 53.2 million people in the United States used illegal drugs in 2018, an increase of 2 million people since 2017. The 2018 survey also found that 16.9 million people reported misusing psychotherapeutics in 2018, and 12.6 million people reported driving under the influence of illegal drugs.ⁱⁱ The 2020 NSDUH found use of illicit drugs in the past year had increased to 59.3 million people or 21.4% of the U.S. population age 12 or older,ⁱⁱⁱ and an increase of 6.1 million people since 2018.

NHTSA’s 2013–2014 National Roadside Survey of Alcohol and Drug Use by Drivers reported that 20.1% of all drivers surveyed on weekend nights tested positive for the presence of some drug, legal and/or illegal, other than alcohol, a statistically significant increase from the 16.3% of drug-positive drivers found in the 2007 survey.^{iv} NHTSA’s study of drug prevalence in road users with serious or fatal injuries admitted to five Level-1 trauma centers or their corresponding Medical Examiner’s offices, found that in the months just prior to the current pandemic 50.8% of the drivers in the study had at least one drug in their system (including alcohol) with 17.6% having multiple drugs in their systems. This increased to 64.7% and 25.3%, respectively, during the pandemic in the second quarter of 2020. During this time cannabis presence increased from 20.8% to 32.7% and opioid presence increased from 7.5% to 13.9% in this sample of drivers.^v Clearly, many drivers on the roads today pose a potential danger to themselves and others because of potentially impairing drugs in their systems.

Prescription and OTC drug use is quite common in America. The National Center for Health Statistics estimated that, from 2015–2018, 48.6% of Americans used at least one prescription medication in the past 30 days, with 24% using three or more prescription medications in the last 30

days and 12.8% using five or more prescription medications in the last 30 days. The most frequently prescribed drugs were analgesics,^{vi} which is reflected in the current opioid epidemic. Drivers increase the risk of drug-impaired driving because they may not be able to distinguish between prescription drugs that are impairing and those that are not.^{vii} Furthermore, the simultaneous use of multiple therapeutic drugs or combining therapeutics with alcohol increases the risk of motor vehicle crashes because of the potential for interaction effects.^{viii}

Another trend fueling concerns about drug-impaired driving is the shift in use, social acceptance, and policies regarding the use of marijuana. Marijuana is defined here as “all substances containing tetrahydrocannabinol.”^{ix} The terms marijuana and cannabis are used interchangeably in this document. From 2001–2002 to 2012–2013, the use of marijuana doubled from 4.1% to 9.5% of the U.S. adult population, with 30% of these users meeting the criteria for marijuana use disorder.^x In 2020, 17.9% of Americans 12 years or older reported using cannabis in the past year (approximately 49.6 million people), and an estimated 5.1% of people 12 and older (approximately 14.2 million people) had a cannabis use disorder.^{xi} Though marijuana is still illegal under federal law, eighteen States and the District of Columbia have now legalized both recreational and medical use of marijuana and seventeen States have legalized the use of medical marijuana. Another thirteen states have legalized marijuana for specific medical conditions.^{xii} In 2018, Canada legalized the recreational use of marijuana at the national level, and Mexico passed a bill legalizing recreational cannabis in 2021. This trend towards legalization has been accompanied by an increase in the presence of marijuana found in drivers. NHTSA’s National Roadside Survey found tetrahydrocannabinol (THC) presence in 12.7% of surveyed drivers in 2013–2014, up from 8.7% in the 2007 survey. In a 2018 study by Washington State, 39.1% of drivers admitted to driving within 3 hours of using marijuana at least once in the previous year, and the biological results from the survey indicated that the presence of marijuana in surveyed drivers had doubled, from approximately 10%, to 20% of all drivers after the state’s implementation of retail marijuana sales.^{xiii} A NHTSA roadside survey in Washington State found similar results, with 7.8% of drivers testing positive for presence of THC prior to the

implementation of legal marijuana in the state. NHTSA found significant increases in THC presence in drivers six months (18.4%) and one year (18.9%) after legalization.^{xiv} While linking the level of marijuana present in biological samples with level of impairment remains challenging, well-established evidence shows that marijuana use detrimentally affects driving-related skills. Marijuana use slows driver reaction time, creates problems with road tracking and maintaining lane position, and decreases cognitive performance and driver attention maintenance. Marijuana use in conjunction with other drugs, such as alcohol, can also have a compounding effect on impairment.^{xv} The current shifts in policy and marijuana use increase the public health concerns regarding drug-impaired driving.

The lack of adequate data to determine the scope and magnitude of the drug impaired driving problem presents a major challenge in addressing the issue of drug-impaired driving.^{xi xvi} Estimates show that comprehensive societal costs for alcohol-impaired driving were approximately \$194 billion in 2010;^{xvii} however, the data required for conducting similar analyses for the comprehensive societal costs of drug-impaired driving are lacking. The data currently available on drug-impaired driving and motor vehicle crashes have many shortcomings.^{xviii} These include inconsistent drug testing policies and procedures across jurisdictions, such as considerable variability in who is tested, what drugs are tested for, detection capabilities of the laboratory, and what specimen matrices (blood, oral fluid, urine, etc.) are used.

In 2009,^{xii} and again in 2017,^{xi} NHTSA recommended that States provide separate statutes for alcohol- and drug-impaired offenses, to provide incentive for “law enforcement officers to pursue a possible drug-impaired driving charge even when a BAC equal to or above the limit of .08 g/dL has already been established,” but few states currently have such statutes. Many jurisdictions only test for drugs when alcohol levels are below *per se* limits that indicate a driver, by law, is intoxicated by alcohol, and forego drug testing when alcohol *per se* limits are met. However, high percentages of specimens in impaired driving cases that were tested only for alcohol are often positive for other drugs, too.^{xix} Some jurisdictions do not perform any drug testing for motor vehicle crashes. Reporting of the toxicology findings is also inconsistent and often lacks sufficient specificity regarding whether it is reporting a screening test or a

confirmation test, and other critical information, such as the drug panels and thresholds of detection used, is often left out. This widespread inconsistency in drug testing and lack of detail in reporting of toxicology on reports of motor vehicle crashes and fatalities creates significant problems for policy makers and traffic safety professionals trying to address the problem of drug-impaired driving.

In many States, the large number of laboratories conducting post-mortem drug testing (typically ordered at the county level by the coroner or medical examiner) often do not look for the same core list of drugs and do not use comparable testing techniques with similar thresholds of detection because there is a lack of standardization regarding the drug panels and detection thresholds used for motor vehicle crashes. This prevents data from different laboratories from being combined to get a clear picture of drug use within the State. Similarly, in many States, individual law enforcement agencies contract with different laboratories which do not screen for the same set of core drugs, nor use comparable testing techniques with similar thresholds of detection. This limits the ability to characterize and monitor/conduct surveillance and better understand the issue of statewide driver drug use. “Currently, the limitations (in the drugged driving data) severely constrain interpretation of the data. Comparisons across labs, States, or years are problematic.” This is reflected at the national level in the FARS data.^{xx}

A recent expert panel on the impact of marijuana on the driving while intoxicated (DWI) system, which included various experts from divisions in the departments of motor vehicles, law enforcement, and the courts and corrections departments as well as government data systems, reported a serious need for more and better data on drug use by drivers as well as standardized laboratory practices for drug toxicology, including which drugs are tested for, what detection thresholds of the drugs are used, confirmation testing results, and comprehensive reporting on the tests conducted and the matrices used.^{xxi} Recent reports from the Governors Highway Safety Association (GHSA) have stressed the urgent need for better, more comprehensive toxicology testing and reporting of toxicology test results for motor vehicle crashes.^{xxii xxiii} This need was also emphasized in NHTSA’s reports to Congress on marijuana-impaired driving (2017)^{xi} and drug-impaired driving (2009),^{xii} and two National Transportation Safety Board

(NTSB) reports on impaired driving.^{xxiv xxv}

Recommendations and Request for Comments

The Center for Forensic Science Research & Education (CFSRE) and the National Safety Council Alcohol, Drugs and Impairment Division (NSC-ADID) report, *Updates for Recommendations for Drug Testing in DUID & Traffic Fatality Investigations* (2016), summarized a survey it conducted of toxicology laboratories from across the country. The survey identified “current practices, capabilities, research needs and gathered information regarding the scope and sensitivity of testing.”^{xxvi} Subsequently, the Drugs, Technology, Pharmacology and Toxicology Section of the National Safety Council’s Alcohol, Drugs and Impairment Division reviewed the survey results and updated their 2013 published recommendations for the toxicology community,^{xxvii} which were published as “Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2017 Update” in the *Journal of Analytical Toxicology*.^{xxviii} These recommendations are referenced in Section 25025 of Public Law 117–58. The CFRSE and NSC-ADID conducted a follow-up survey of laboratories in 2020, after which the recommendations were updated and published as “Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update” in the *Journal of Analytical Toxicology*.^{xxix} These recommendations address the identified toxicology needs for drug-impaired driving cases. Coupled with comprehensive reporting of the toxicology findings, the widespread use of these toxicology recommendations could greatly enhance understanding of the scope and magnitude of drug-impaired driving and help traffic safety professionals better address this vital public health issue.^{xxx} The toxicology recommendations in the 2021 Update are available, free of charge, online at: <https://pubmed.ncbi.nlm.nih.gov/34086916/>.

Given the growing national concern over drug-impaired driving and the clear need for standardized drug-impaired driving toxicological testing and comprehensive reporting on the toxicological results, NHTSA is preparing a Report to Congress on Drug-Impaired Driving Data Collection that identifies the barriers to States in providing the toxicological data to FARS as described in the NSC-ADID document, recommends solutions to overcome those barriers, and describes

the steps the Department of Transportation and NHTSA will take to assist States in improving toxicology testing in cases of motor vehicle crashes and reporting of alcohol and drug toxicology results in cases of motor vehicle crashes provided to FARS. Our first step in producing this report is the collection of information from the public on barriers and possible solutions. NHTSA therefore seeks public comment on any barriers that States may have to adopting these recommendations, and any comments on what is needed to overcome these barriers.

As previously noted, the *Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update* were developed by an expert panel of toxicologists based on the results of a national survey of toxicology laboratories. These voluntary recommendations are for forensic toxicological drug testing and reporting for all drivers, motorcycle and moped operators, bicyclists and pedestrians involved in fatal motor vehicle crashes, and all drivers who are arrested or convicted for impaired operation of motor vehicles, regardless of their tested Blood Alcohol Concentration (BAC) or Breath Alcohol Concentration (BrAC). The recommendations provide standardized lists of drugs, matrices (blood, oral fluid, urine, etc.), and detection threshold levels for testing. The guidelines include two tiers of drugs for testing: Tier 1 drugs (Table II in the document) are drugs that are found throughout the country and that should be tested for in all jurisdictions; Tier 2 drugs (Table III in the document) are less common or predominantly found in specific areas of the country, so they may only need to be routinely tested for in those localities or on a case-by-case basis. NHTSA believes that the voluntary adoption of these toxicology guidelines would greatly improve data collection, and support future initiatives by a wide variety of traffic safety stakeholders using this toxicological data to help reduce drug-impaired driving. It is critical that comprehensive and consistent data on this vital public health issue are available for use in all parts of the impaired-driving system, from law enforcement to adjudication and treatment to public policy.

Drug impaired driving is a growing concern; however, the information currently available on the scope and magnitude of drug impaired driving is unclear. Today, there is great variation across the country regarding which drivers are tested for drug use, what specimens are collected for testing, what

drugs are tested for, and what threshold detection levels are used for drug tests. Comprehensive and consistent toxicological data is needed to better inform the public and public policy on this growing public health problem. This testing and data are also essential to increasing the effectiveness of law enforcement and adjudication efforts in drug-impaired driving cases and to making America's roads safer for the driving public.

In support of our efforts to improve the toxicological data provided to FARS and the States, reduce the problem of drug-impaired driving, and "assist States in their efforts to increase public awareness of the dangers of drug-impaired driving,"^{xxxi} NHTSA hereby requests public comment on the following:

(1) Identification of any barriers or challenges that States currently encounter in submitting alcohol and drug toxicology results to the Fatality Analysis Reporting System (FARS).

(2) Suggestions for overcoming those current barriers and challenges identified to improve the delivery of data to the FARS.

(3) Identification of any barriers or challenges that States may encounter in collecting the toxicology data as described in *Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update* (<https://pubmed.ncbi.nlm.nih.gov/34086916/>) and submitting those alcohol and drug toxicology results to the Fatality Analysis Reporting System (FARS).

(4) Suggestions for overcoming those barriers and challenges identified for collecting the toxicological data as described in the *Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update* to improve the delivery of the data to the FARS.

Notes

ⁱ Couper, F. and Logan, B. 2004. Drugs and Human Performance. DOT HS 809 725. National Highway Traffic Safety Administration. Washington, DC. https://www.wsp.wa.gov/breathtest/docs/webdms/DRE_Forms/Publications/drug/Human_Performance_Drug_Fact_Sheets-NHTSA.pdf.

ⁱⁱ Center for Behavioral Health Statistics and Quality. 2019. *Results from the 2018 National Survey on Drug Use and Health*. SAMHSA, Rockville, MD. <https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables>.

ⁱⁱⁱ Substance Abuse and Mental Health Services Administration. (2021). *Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health* (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center

for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from <https://www.samhsa.gov/data/>.

^{iv} Kelley-Baker, T., Berning, A., Ramirez, A., Lacey, J., Carr, K., Waehner, G., Moore, C., Pell, K., Yao, J., and Compton, R. 2017. 2013–2014 National Roadside Survey of Alcohol and Drug Use by Drivers: Drug Results. DOT HS 812 411. National Highway Traffic Safety Administration. Washington, DC. https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/13013-nrs_drug_092917_v6_tag.pdf.

^v Thomas, F.D., Berning, A., Darrah, J., Graham, L., Blomberg, R., Griggs, C., Crandall, M., Schulman, C., Kozar, R., Neavyn, M., Cunningham, K., Ehsani, J., Fell, J., Whitehill, J., Babu, K., Lai, J., and Rayner, M. (2020, October). *Drug and alcohol prevalence in seriously and fatally injured road users before and during the COVID-19 public health emergency* (Report No. DOT HS 813 018). National Highway Traffic Safety Administration.

^{vi} Centers for Disease Control and Prevention. 2019. National Center for Health Statistics. Therapeutic Drug Use. <https://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm>.

^{vii} Smith, R., Turturici, M. and Camden, M. 2018. Countermeasures Against Prescription and Over-the-Counter-Impaired Driving. AAA Foundation for Traffic Safety. Washington, DC. http://aaafoundation.org/wp-content/uploads/2018/10/VTTI_Rx_OTC_FinalReport_VTTI-FINAL-complete-9.20.pdf.

^{viii} Alda, A., Pharm, D., and Morse, M. 2008. Multiple Medications and vehicle Crashes: Analysis of Databases. DOT HS 810 858. National Highway Traffic Safety Administration. Washington, DC.

^{ix} Current legislation (Section 25025, Pub. L. 17–58) references the definition of marijuana in the F.A.S.T. Act, Section 4008 (d). <https://www.govinfo.gov/content/pkg/PLAW-114publ94/html/PLAW-114publ94.htm>.

^x National Institutes of Health. 2015. Prevalence of Marijuana Use Among U.S. Adults Doubles Over Past Decade. <https://www.nih.gov/news-events/news-releases/prevalence-marijuana-use-among-us-adults-doubles-over-past-decade>.

^{xi} National Institutes of Health. 2022. <https://www.drugabuse.gov/publications/research-reports/marijuana/what-scope-marijuana-use-in-united-states>.

^{xii} Insurance Institute for Highway Safety. Alcohol and drugs: Marijuana laws. <https://www.iihs.org/topics/alcohol-and-drugs>.

^{xiii} Grondel, D., Hoff, S., and Doane, D. Marijuana Use, Alcohol Use and Driving in Washington State. 2018. Washington Traffic Safety Commission. http://wtsc.wa.gov/wp-content/uploads/dlm_uploads/2018/05/Marijuana-and-Alcohol-Involvement-in-Fatal-Crashes-in-WA_FINAL.pdf.

^{xiv} Ramirez, A., Berning, A., Carr, K., Schere, M., Lacey, J., Kelley-Baker, T., and Fisher, D. 2016. Marijuana, Other Drugs, and Alcohol Use by Drivers in Washington State. DOT HS 812 299. National Highway Traffic Safety Administration. Washington, DC. <https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/812299-washingtonstatedrugstudy.pdf>.

^{xv} Compton, R. 2017. Marijuana-Impaired Driving: A Report to Congress. DOT HS 812 440. National Highway Traffic Safety Administration. Washington, DC. <https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/812440-marijuana-impaired-driving-report-to-congress.pdf>.

^{xvi} Compton, R., Vegega, M., and Smither, D. 2009. Drug-Impaired Driving: Understanding the Problem and Ways to Reduce It—A Report to Congress. DOT HS 811 268. National Highway Traffic Safety Administration. Washington, DC. <https://rosap.nhtl.bts.gov/view/dot/1949>.

^{xvii} Blincocoe, L.J., Miller, T.R., Zaloshnja, E., & Lawrence, B.A. (2015, May). *The economic and societal impact of motor vehicle crashes, 2010 (Revised)* (Report No. DOT HS 812 013). Washington, DC: National Highway Traffic Safety Administration.

^{xviii} Berning, A. and Smither, D. 2014. Understanding the Limitations of Drug Test Information, Reporting, and Testing Practices in Fatal Crashes. Traffic Safety Facts Research Note DOT HS 812 072. National Highway Traffic Safety Administration. Washington, DC. <https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/812072-understandlimitsdrugtest-researchnote.pdf>.

^{xix} Limoges, J., Tandy, A., and Brown, H. 2009. A Retrospective Study of Drug Prevalence in Alcohol Related Driving Arrests. Presented at the annual meeting of the American Academy of Forensic Sciences.

^{xx} Berning, A., Smith, R.C., Drexler, M., & Wochinger, K. (2022, March). *Drug testing and traffic safety: What you need to know* (Report No. DOT HS 813 264). National Highway Traffic Safety Administration.

^{xxi} National Highway Traffic Safety Administration, Governors Highway Safety Association, and Volpe National Transportation Systems Center. 2017. Impact of the Legalization and Decriminalization of Marijuana on the DWI System: Highlights from the Expert Panel Meeting. National Highway Traffic Safety Administration. Washington, DC. https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/expert_dwi_panel.pdf.

^{xxii} Hedlund, J. 2017. Drug-Impaired Driving: A Guide for the States. Governors Highway Safety Association and Foundation for Advancing Alcohol Responsibility. <https://www.ghsa.org/resources/drugged-driving-2017>.

^{xxiii} Hedlund, J. 2018. Drug-Impaired Driving: Marijuana and Opioids Raise Critical Issues for States. Governors Highway Safety Association and Foundation for Advancing Alcohol Responsibility. <https://www.ghsa.org/resources/DUID18>.

^{xxiv} 2013 NTSB Report, *Reaching Zero: Actions to Eliminate Alcohol-Impaired Driving* (<https://www.ntsb.gov/safety/safety-studies/Documents/SR1301.pdf>).

^{xxv} 2018 NTSB Report, *Pickup Truck Centerline Crossover Collision With Medium Size Bus on US Highway 83, Concan, Texas, March 29, 2017* (<https://www.ntsb.gov/investigations/AccidentReports/Reports/HAR1802.pdf>).

^{xxvi} D'Orazio, A., Scott, K., Mohr, A. and Logan, B. 2016. Updates for Recommendations for Drug testing in DUID & Traffic Fatality Investigations. The Center

for Forensic Science Research & Education at the Frederic Rieders Family Foundation, 2300 Stratford Avenue, Willow Grove, PA 19090. <https://www.forensicscienceeducation.org/wp-content/uploads/2016/04/Full-Survey-Report.pdf>.

^{xxvii} Logan, B., Lowrie, K., Turri, J., Yeakel, Limoges, J., Miles, A., Scarneo, C., Kerrigan, S., and Farrell, L. 2013. Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities. *Journal of Analytical Toxicology*. Volume 37. August 2013, Pages 552–558.

^{xxviii} Logan, B., D'Orazio, A., Mohr, A., Limoges, J., Miles, A., Scarneo, C., Kerrigan, S., Liddicoat, L., Scott, K., and Huestis, M. 2018. Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2017 Update. *Journal of Analytical Toxicology*. Volume 42. Issue 2. March 2018, Pages 63–68. <https://academic.oup.com/jat/article/42/2/63/4653729>.

^{xxix} D'Orazio, A., Mohr, A., Chan-Hosokawa, A., Harper, C., Huestis, M., Limoges, J., Miles, A., Scarneo, C., Kerrigan, S., Liddicoat, L., Scott, K., Logan, B. Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update. *Journal of Analytical Toxicology*. July, 2021. 45(6):529–536. <https://pubmed.ncbi.nlm.nih.gov/34086916/>.

^{xxx} Watson, M.W. and Mann, R.E. 2018. Harm reduction and drug-impaired driving: sharing the road?. *Drugs: Education Prevention and Policy*. 25:2, 105–108. <https://doi.org/10.1080/09687637.2017.1344620>.

^{xxxi} Fixing America's Surface Transportation Act, Public Law 114–94, 4009 (2015).

Authority: 44 U.S.C. Section 3506(c)(2)(A).

Issued in Washington, DC.

Nanda Narayanan Srinivasan,
Associate Administrator, Research and Program Development.

[FR Doc. 2022–08776 Filed 4–22–22; 8:45 am]

BILLING CODE 4910–59–P

DEPARTMENT OF THE TREASURY

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Internal Revenue Service Form 7203

AGENCY: Departmental Offices, U.S. Department of the Treasury.

ACTION: Notice.

SUMMARY: The Department of the Treasury will submit the following information collection requests to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The public is invited to submit comments on these requests.

DATES: Comments must be received on or before May 25, 2022.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

FOR FURTHER INFORMATION CONTACT: Copies of the submissions may be obtained from Molly Stasko by emailing PRA@treasury.gov, calling (202) 622–8922, or viewing the entire information collection request at www.reginfo.gov.

SUPPLEMENTARY INFORMATION:

Title: S Corporation Shareholder Stock and Debt Basis Limitations.

OMB Control Number: 1545–2302.

Type of Review: Extension without change of a currently approved collection.

Description: Internal Revenue Code (IRC) Section 1366 determines the shareholder's tax liability from an S corporation. IRC Section 1367 details the adjustments to basis including the increase and decrease in basis, income items included in basis, the basis of indebtedness, and the basis of inherited stock. Shareholders will use Form 7203 to calculate their stock and debt basis, ensuring the losses and deductions are accurately claimed.

Form Number: IRS Form 7203.

Affected Public: Individuals and Households.

Estimated Number of Respondents: 70,000.

Frequency of Response: On Occasion.
Estimated Total Number of Annual Responses: 70,000.

Estimated Time per Response: 3 hours 46 minutes.

Estimated Total Annual Burden Hours: 257,600.

Authority: 44 U.S.C. 3501 *et seq.*

Molly Stasko,

Treasury PRA Clearance Officer.

[FR Doc. 2022–08693 Filed 4–22–22; 8:45 am]

BILLING CODE 4830–01–P

DEPARTMENT OF THE TREASURY

Agency Information Collection Activities; Submission for OMB Review; Community Development Financial Institutions Funds Certificate of Material Events Form

AGENCY: Departmental Offices, U.S. Department of the Treasury.

ACTION: Notice.